Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
Top Cited Papers
- 9 June 2011
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 364 (23) , 2199-2207
- https://doi.org/10.1056/nejmoa1009370
Abstract
The Extension for Community Healthcare Outcomes (ECHO) model was developed to improve access to care for underserved populations with complex health problems such as hepatitis C virus (HCV) infection. With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases. We conducted a prospective cohort study comparing treatment for HCV infection at the University of New Mexico (UNM) HCV clinic with treatment by primary care clinicians at 21 ECHO sites in rural areas and prisons in New Mexico. A total of 407 patients with chronic HCV infection who had received no previous treatment for the infection were enrolled. The primary end point was a sustained virologic response. A total of 57.5% of the patients treated at the UNM HCV clinic (84 of 146 patients) and 58.2% of those treated at ECHO sites (152 of 261 patients) had a sustained viral response (difference in rates between sites, 0.7 percentage points; 95% confidence interval, −9.2 to 10.7; P=0.89). Among patients with HCV genotype 1 infection, the rate of sustained viral response was 45.8% (38 of 83 patients) at the UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites (P=0.57). Serious adverse events occurred in 13.7% of the patients at the UNM HCV clinic and in 6.9% of the patients at ECHO sites. The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities. Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat. (Funded by the Agency for Healthcare Research and Quality and others.)Keywords
This publication has 23 references indexed in Scilit:
- Public health impact of antiviral therapy for hepatitis C in the United States†Hepatology, 2009
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- Rate and predictors of treatment prescription for hepatitis CGut, 2007
- Susceptibility to Hepatitis A in Patients With Chronic Liver Disease Due to Hepatitis C Virus Infection: Missed Opportunities for Vaccination *Hepatology, 2005
- Primary Care Physicians Who Treat Blacks and WhitesNew England Journal of Medicine, 2004
- Health Care in America — Still Too Separate, Not Yet EqualNew England Journal of Medicine, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Racial Disparities in Access to Renal Transplantation — Clinically Appropriate or Due to Underuse or Overuse?New England Journal of Medicine, 2000